Pascal Biosciences Inc. owns patent pending intellectual property on three major technologies that target cancer, autoimmunity, and infectious disease. The common thread linking these technologies is the mobilization or modulation of the immune system. The three technologies relate to the following:
- Calcium Channel Blockers – Pascal aims to identify new calcium channel blockers which can control immune system activation in combatting cancers, infections and autoimmune diseases. Activities of these channels regulate the concentration of calcium in cells and, ultimately, regulate activation of these cells.
- Major Histocompatibility Complex I (MHC-I) – Cancer cells escape immune recognition by downregulating MHC-I expression. Pascal has identified and is optimizing small molecules that restore MHC-I expression in cancer cells.
- CD74 – Vaccines depend upon efficient processing and presentation of infectious organism antigens to the immune system. Pascal is harnessing the endolysosomal-targeting capacity of CD74 to enhance delivery of the antigens to the antigen processing pathway of dendritic cells.
Pascal is currently advancing all three programs.